IL-1 contributes to the anti-cancer efficacy of ingenol mebutate

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Le, Thuy T ^a   Skak, Kresten ^b   Schroder, Kate ^c   Schroder, Wayne A ^a   Boyle, Glen M ^a   Pierce, Carly J ^a   Suhrbier, Andreas ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Leo Pharma ^*  (Denmark)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INGENOL MEBUTATE; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; 3-INGENYL ANGELATE; ANTINEOPLASTIC AGENT; DITERPENE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MYD88 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER RECURRENCE; CELL KILLING; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INNATE IMMUNITY; KERATINOCYTE; MELANOMA B16; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN INDUCTION; RECURRENCE RISK; ANIMAL; C57BL MOUSE; CELLULAR IMMUNITY; DRUG EFFECTS; GENE DELETION; GENETICS; IMMUNOLOGY; MELANOMA; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DITERPENES; FEMALE; GENE DELETION; IMMUNITY, CELLULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MELANOMA; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM RECURRENCE, LOCAL;

EID: 84964677979     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153975     Document Type: Article

References (62)

1. Zarchi K, Jemec GB. Ingenol mebutate: from common weed to cancer cure. Curr Probl Dermatol. 2015; 46: 136-142. doi: 10.1159/000366549 PMID: 25561218
2. Ogbourne SM, Parsons PG. The value of nature's natural product library for the discovery of New Chemical Entities: the discovery of ingenol mebutate. Fitoterapia. 2014; 98: 36-44. doi: 10.1016/j.fitote.2014.07.002 PMID: 25016953
3. Tzogani K, Nagercoil N, Hemmings RJ, Samir B, Gardette J, Demolis P, et al. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, nonhypertrophic actinic keratosis in adults: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP). Eur J Dermatol. 2014; 24: 457-463. doi: 10.1684/ejd. 2014.2368 PMID: 25115145
4. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006; 155: 9-22. PMID: 16792746
5. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000; 42: 23-24. PMID: 10607353
6. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013; 149: 666-670. doi: 10.1001/jamadermatol.2013.2766 PMID: 23553119
7. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012; 366: 1010-1019. doi: 10.1056/NEJMoa1111170 PMID: 22417254
8. Alchin DR. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol Ther (Heidelb). 2014; 4: 157-164.
9. Cozzi SJ, Le TT, Ogbourne SM, James C, Suhrbier A. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res. 2013; 305: 79-83. doi: 10.1007/s00403-012-1270-0 PMID: 22871992
10. Le TT, Gardner J, Hoang-Le D, Schmidt CW, MacDonald KP, Lambley E, et al. Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine. 2009; 27: 3053-3062. doi: 10.1016/j.vaccine.2009.03.025 PMID: 19428919
11. Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, et al. The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol. 2011; 164: 633-636. doi: 10.1111/j.1365-2133.2010.10184.x PMID: 21375515
12. Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010; 51: 99-105. doi: 10.1111/j.1440-0960.2010.00626.x PMID: 20546215
13. Cantisani C, Paolino G, Cantoresi F, Faina V, Richetta AG, Calvieri S. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%. Dermatol Ther. 2014; 27: 352-354. doi: 10. 1111/dth.12148 PMID: 25052730
14. Kedei N, Lundberg DJ, Toth A, Welburn P, Garfield SH, Blumberg PM. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004; 64: 3243-3255. PMID: 15126366
15. Freiberger SN, Cheng PF, Iotzova-Weiss G, Neu J, Liu Q, Dziunycz P, et al. Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. Mol Cancer Ther. 2015; 14: 2132-2142. doi: 10.1158/1535-7163.MCT-15-0023-T PMID: 26116359
16. Ogbourne SM, Suhrbier A, Jones B, Cozzi SJ, Boyle GM, Morris M, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004; 64: 2833-2839. PMID: 15087400
17. Cozzi SJ, Ogbourne SM, James C, Rebel HG, de Gruijl FR, Ferguson B, et al. Ingenol mebutate fielddirected treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol. 2012; 132: 1263-1271. doi: 10.1038/jid.2011.418 PMID: 22189786
18. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-DUMMY, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009; 60: 934-943. doi: 10.1016/j.jaad.2009.01.008 PMID: 19467365
19. Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009; 50: 16-22. doi: 10.1111/j.1440-0960.2008. 00497.x PMID: 19178487
20. Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed Rainger G. The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 2008; 57: 1241-1251. doi: 10.1007/s00262-008-0458-9 PMID: 18265980
21. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol. 2006; 177: 8123-8132. PMID: 17114487
22. La Linn M, Bellett AJ, Parsons PG, Suhrbier A. Complete removal of mycoplasma from viral preparations using solvent extraction. J Virol Methods. 1995; 52: 51-54. PMID: 7539444
23. Poo YS, Nakaya H, Gardner J, Larcher T, Schroder WA, Le TT, et al. CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis. J Virol. 2014; 88: 6862-6872. doi: 10.1128/JVI.03364-13 PMID: 24696480
24. Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum. 2012; 64: 3553-3563. doi: 10.1002/art.34631 PMID: 22833339
25. Gross O. Measuring the inflammasome. Methods Mol Biol. 2012; 844: 199-222. doi: 10.1007/978-1-61779-527-5-15 PMID: 22262445
26. Hayashi T, Chan M, Norton JT, Wu CC, Yao S, Cottam HB, et al. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res. 2011; 21: 66-75. doi: 10.1097/CMR.0b013e328340ce6c PMID: 21030882
27. Murphy JE, Morales RE, Scott J, Kupper TS. IL-1 alpha, innate immunity, and skin carcinogenesis: the effect of constitutive expression of IL-1 alpha in epidermis on chemical carcinogenesis. J Immunol. 2003; 170: 5697-5703. PMID: 12759452
28. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003; 100: 2645-2650. PMID: 12598651
29. Bjorkdahl O, Wingren AG, Hedhund G, Ohlsson L, Dohlsten M. Gene transfer of a hybrid interleukin-1 beta gene to B16 mouse melanoma recruits leucocyte subsets and reduces tumour growth in vivo. Cancer Immunol Immunother. 1997; 44: 273-281. PMID: 9247562
30. Bjorkdahl O, Dohlsten M, Sjogren HO. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wildtype B16 tumor. Cancer Gene Ther. 2000; 7: 1365-1374. PMID: 11059695
31. Triozzi PL, Aldrich W. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma. Anticancer Res. 2010; 30: 345-354. PMID: 20332438
32. Sonego F, Castanheira FV, Czaikoski PG, Kanashiro A, Souto FO, Franca RO, et al. MyD88-, but not Nod1-and/or Nod2-deficient mice, show increased susceptibility to polymicrobial sepsis due to impaired local inflammatory response. PLoS One. 2014; 9: e103734. doi: 10.1371/journal.pone.0103734 PMID: 25084278
33. Feng Y, Zou L, Si R, Nagasaka Y, Chao W. Bone marrow MyD88 signaling modulates neutrophil function and ischemic myocardial injury. Am J Physiol Cell Physiol. 2010; 299: C760-769. doi: 10.1152/ajpcell.00155.2010 PMID: 20631245
34. Jarchum I, Liu M, Shi C, Equinda M, Pamer EG. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun. 2012; 80: 2989-2996. doi: 10.1128/IAI.00448-12 PMID: 22689818
35. Chen LC, Wang LJ, Tsang NM, Ojcius DM, Chen CC, Ouyang CN, et al. Tumour inflammasomederived IL-1beta recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med. 2012; 4: 1276-1293. doi: 10.1002/emmm.201201569 PMID: 23065753
36. Watson RW, Rotstein OD, Parodo J, Bitar R, Marshall JC. The IL-1 beta-converting enzyme (caspase-1) inhibits apoptosis of inflammatory neutrophils through activation of IL-1 beta. J Immunol. 1998; 161: 957-962. PMID: 9670975
37. Prince LR, Allen L, Jones EC, Hellewell PG, Dower SK, Whyte MK, et al. The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival. Am J Pathol. 2004; 165: 1819-1826. PMID: 15509550
38. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 1992; 80: 2012-2020. PMID: 1382715
39. Bakele M, Joos M, Burdi S, Allgaier N, Poschel S, Fehrenbacher B, et al. Localization and functionality of the inflammasome in neutrophils. J Biol Chem. 2014; 289: 5320-5329. doi: 10.1074/jbc.M113. 505636 PMID: 24398679
40. Smith RJ, Bowman BJ, Speziale SC. Interleukin-1 stimulates granule exocytosis from human neutrophils. Int J Immunopharmacol. 1986; 8: 33-40. PMID: 2420732
41. Yagisawa M, Yuo A, Kitagawa S, Yazaki Y, Togawa A, Takaku F. Stimulation and priming of human neutrophils by IL-1 alpha and IL-1 beta: complete inhibition by IL-1 receptor antagonist and no interaction with other cytokines. Exp Hematol. 1995; 23: 603-608. PMID: 7601250
42. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39: 1003-1018. doi: 10.1016/j.immuni.2013.11.010 PMID: 24332029
43. Wu TT, Tai YT, Cherng YG, Chen TG, Lin CJ, Chen TL, et al. GATA-2 transduces LPS-induced il-1beta gene expression in macrophages via a toll-like receptor 4/MD88/MAPK-dependent mechanism. PLoS One. 2013; 8: e72404. doi: 10.1371/journal.pone.0072404 PMID: 23940812
44. Shaw MH, Kamada N, Kim YG, Nunez G. Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine. J Exp Med. 2012; 209: 251-258. doi: 10.1084/jem.20111703 PMID: 22291094
45. Zheng Y, Humphry M, Maguire JJ, Bennett MR, Clarke MC. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity. 2013; 38: 285-295. doi: 10.1016/j.immuni.2013.01.008 PMID: 23395675
46. Rauschmayr T, Groves RW, Kupper TS. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation. Proc Natl Acad Sci U S A. 1997; 94: 5814-5819. PMID: 9159157
47. Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. J Drugs Dermatol. 2012; 11: 1181-1192. PMID: 23134983
48. Neville ME, Pezzella KM, Schmidt K, GalbraithW, Ackerman N. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. II. Mechanism of inhibition: the role of polymorphonuclear leukocytes. Cytokine. 1990; 2: 456-463. PMID: 1966551
49. van Egmond M, Bakema JE. Neutrophils as effector cells for antibody-based immunotherapy of cancer. Semin Cancer Biol. 2013; 23: 190-199. doi: 10.1016/j.semcancer.2012.12.002 PMID: 23287459
50. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, et al. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013; 122: 3160-3164. doi: 10.1182/blood-2013-04-497446 PMID: 23980063
51. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-241. PMID: 16407889
52. Dostert C, Guarda G, Romero JF, Menu P, Gross O, Tardivel A, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One. 2009; 4: e6510. doi: 10.1371/journal.pone.0006510 PMID: 19652710
53. Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A. 2010; 107: 19449-19454. doi: 10.1073/pnas.1008155107 PMID: 20974980
54. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity. 2012; 36: 388-400. doi: 10.1016/j.immuni.2012.01.018 PMID: 22444631
55. Cullen SP, Kearney CJ, Clancy DM, Martin SJ. Diverse Activators of the NLRP3 Inflammasome Promote IL-1beta Secretion by Triggering Necrosis. Cell Rep. 2015; 11: 1535-1548. doi: 10.1016/j.celrep.2015.05.003 PMID: 26027935
56. Winkler S, Rosen-Wolff A. Caspase-1: an integral regulator of innate immunity. Semin Immunopathol. 2015; 37: 419-427. doi: 10.1007/s00281-015-0494-4 PMID: 26059719
57. Toda Y, Tsukada J, Misago M, Kominato Y, Auron PE, Tanaka Y. Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol. 2002; 168: 1984-1991. PMID: 11823535
58. Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009; 206: 1029-1036. doi: 10.1084/jem.20082481 PMID: 19364880
59. Otten MA, Bakema JE, Tuk CW, Glennie MJ, Tutt AL, Beelen RH, et al. Enhanced FcalphaRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells. Eur J Immunol. 2012; 42: 1815-1821. doi: 10.1002/eji.201141982 PMID: 22535639
60. Li L, Shukla S, Lee A, Garfield SH, Maloney DJ, Ambudkar SV, et al. The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res. 2010; 70: 4509-4519. doi: 10.1158/0008-5472.CAN-09-4303 PMID: 20460505
61. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J Biol Chem. 2014; 289: 35237-35245. doi: 10.1074/jbc.R114.619304 PMID: 25391648
62. Cavanagh LL, Halliday GM. Dendritic epidermal T cells in ultraviolet-irradiated skin enhance skin tumor growth by inhibiting CD4+ T-cell-mediated immunity. Cancer Res. 1996; 56: 2607-2615. PMID: 8653705